Promising time ahead for OCL.
The company is really positioning itself to cash in on the move by enterprises to use software-as-a-service. Short term revenue growth may be lower, but the pay-off is annuity style income for years ahead.
Bigger player, TNE, goes from strength to strength. It commands a Net Profit Margin of 14.5% (and says this is likely to improve), superior to OCL's 10%.
However, OCL are committing 23% of revenue to R & D, while TNE is pulling back below 20%. (TNE state that the industry average in 10 - 12%). This should give OCL some IP clout to command some pricing power for its quality products.
OCL seems to have gone unnoticed by analyst (so far). While TNE trades on a forward P/E of about 24 (assumes EPS of 10 cents), OCL trades on a forward P/E of about 15 (assumes 5 cents EPS). OCL has stated 2H2014 is expected to be stronger than 1H2014.
A re-rating is underway IMO.
- Forums
- ASX - By Stock
- OCL
- is anyone out there
is anyone out there, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OCL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$17.52 |
Change
0.200(1.15%) |
Mkt cap ! $1.408B |
Open | High | Low | Value | Volume |
$17.38 | $17.70 | $17.38 | $1.311M | 74.89K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 124 | $17.51 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.66 | 737 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7125 | 2.750 |
2 | 1356 | 2.710 |
2 | 1194 | 2.600 |
1 | 2997 | 2.510 |
2 | 44658 | 2.500 |
Price($) | Vol. | No. |
---|---|---|
2.780 | 3 | 1 |
2.790 | 3 | 1 |
2.800 | 5003 | 2 |
2.850 | 2206 | 1 |
2.950 | 354 | 1 |
Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
Featured News
OCL (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online